Senators question FDA nominee as agency issues rule to cut animal testing

The latest FDA briefing highlighted two key developments: a Senate hearing on the agency’s next leader and a new regulation targeting animal testing.

During the confirmation hearing, senators pressed the Trump administration’s nominee on a range of issues, seeking clarity on the candidate’s approach to drug approvals and public health priorities.

The FDA also released a rule intended to reduce the use of animals in research, outlining alternative methods and encouraging the adoption of non-animal testing strategies.

These updates underscore ongoing regulatory focus on both leadership and ethical considerations in drug development.